{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=12&state=California",
    "query": {
      "state": "California",
      "city": "Sacramento",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 5547,
    "total_pages": 555,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=13&state=California&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=11&state=California&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T20:53:33.284Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01500278",
      "title": "Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol (CZP)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Adalimumab (ADA)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Methotrexate (MTX)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "UCB Pharma SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 915,
      "start_date": "2011-12",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-10-27T20:53:33.284Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01500278"
    },
    {
      "nct_id": "NCT02481206",
      "title": "Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sudden Cardiac Death",
        "Sudden Cardiac Arrest"
      ],
      "interventions": [
        {
          "name": "Wearable Cardioverter Defibrillator",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Zoll Medical Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2015-06",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-10-27T20:53:33.284Z",
      "location_count": 31,
      "location_summary": "Corona, California • Downey, California • Escondido, California + 28 more",
      "locations": [
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02481206"
    },
    {
      "nct_id": "NCT02750826",
      "title": "Breast Cancer WEight Loss Study (BWEL Study)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Ductal Carcinoma In Situ",
        "Invasive Breast Carcinoma",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Synchronous Bilateral Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Health Education Program",
          "type": "OTHER"
        },
        {
          "name": "Weight Loss Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 3177,
      "start_date": "2016-09-16",
      "completion_date": "2030-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-27T20:53:33.284Z",
      "location_count": 1464,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 921 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02750826"
    },
    {
      "nct_id": "NCT07281495",
      "title": "Taldefgrobep Alfa in Adults With Overweight and Obesity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Taldefgrobep Alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biohaven Therapeutics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 150,
      "start_date": "2025-11-24",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-10-27T20:53:33.284Z",
      "location_count": 20,
      "location_summary": "Chula Vista, California • Montclair, California • Sacramento, California + 17 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07281495"
    },
    {
      "nct_id": "NCT00788073",
      "title": "Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "STX209",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seaside Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "6 Years to 40 Years"
      },
      "enrollment_count": 63,
      "start_date": "2008-11",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2013-05-06",
      "last_synced_at": "2026-10-27T20:53:33.284Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00788073"
    },
    {
      "nct_id": "NCT05101356",
      "title": "A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Adenocarcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Metastatic Adenocarcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Recurrent Adenocarcinoma",
        "Recurrent Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Antineoplastic Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2021-01-13",
      "completion_date": "2034-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-10-27T20:53:33.284Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05101356"
    },
    {
      "nct_id": "NCT05035212",
      "title": "Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lower Respiratory Tract Illness"
      ],
      "interventions": [
        {
          "name": "RSVpreF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 38861,
      "start_date": "2021-08-31",
      "completion_date": "2027-01-18",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-10-27T20:53:33.284Z",
      "location_count": 176,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 119 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05035212"
    },
    {
      "nct_id": "NCT00476112",
      "title": "A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Atrial Flutter"
      ],
      "interventions": [
        {
          "name": "Vernakalant Injection 20 mg/mL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advanz Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2003-08",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2008-04-02",
      "last_synced_at": "2026-10-27T20:53:33.284Z",
      "location_count": 5,
      "location_summary": "Sacramento, California • Lansing, Michigan • Richmond, Virginia + 1 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        },
        {
          "city": "Marshfield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00476112"
    },
    {
      "nct_id": "NCT02134951",
      "title": "Biomarker Assessment of Glutamatergic Target Engagement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy Controls"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 65,
      "start_date": "2014-05",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-10-27T20:53:33.284Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • New Haven, Connecticut • New York, New York",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02134951"
    },
    {
      "nct_id": "NCT00003857",
      "title": "Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "26 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "26 Years to 120 Years · Female only"
      },
      "enrollment_count": 636,
      "start_date": "1999-12",
      "completion_date": "2022-05-20",
      "has_results": false,
      "last_update_posted_date": "2022-05-25",
      "last_synced_at": "2026-10-27T20:53:33.284Z",
      "location_count": 305,
      "location_summary": "Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 235 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003857"
    }
  ]
}